To042antiproteinuric Effect of Sparsentan, a Dual Angiotensin Ii and Endothelin Type a Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (fsgs): a Subgroup Analysis of the Duet Trial
Year: 2017
Type: conference-abstract
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2617438993
